Yabao Pharmaceutical: Metoprolol Hydrochloride Tablet Passed Generic Drug Consistency Evaluation

Yabao Pharmaceutical announced that its controlling subsidiary, Taiyuan Pharmaceutical, has received the approval and issuance of the Drug Supplementary Application Approval Notice for Metoprolol Hydrochloride Tablets by the National Medical Products Administration. The drug has passed the evaluation of generic drug quality and efficacy consistency. In 2023, the domestic sales of Metoprolol Hydrochloride Tablets are expected to be approximately RMB 82.18 million, with sales of approximately RMB 57.76 million in the public medical market and RMB 24.42 million in retail pharmacies. Currently, besides the company, there are 6 other enterprises in China that have passed the consistency evaluation of this drug. The company has invested approximately RMB 2.6 million in research and development expenses for this project.